Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Stage/Subtype:  recurrent non-small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 166 for your search:
Start Over
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, NCT02154490
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9090-14, NCI-2013-01034, NCT01798485
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00079, NCI-2014-00422, 2013-001676-38, NCT01933932
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PPHM 1202, NCI-2014-00363, 2013-003953-13, NCT01999673
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D5160C00003, NCI-2014-02081, NCT02151981
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients With Recurrent Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OER-TH-036, NCI-2011-03306, NCT01471964
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CO-1686-008, NCI-2012-00742, NCT01526928
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients with Stage II-IIIB Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1058, NCI-2012-01224, NCT01629498
Start Over